Related references
Note: Only part of the references are listed.Understanding the Genomic Structure of Copy-Number Variation of the Low-Affinity Fcγ Receptor Region Allows Confirmation of the Association of FCGR3B Deletion with Rheumatoid Arthritis
Raheleh Rahbari et al.
HUMAN MUTATION (2017)
Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma
Vaishalee P. Kenkre et al.
CLINICAL CANCER RESEARCH (2016)
Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism
Guillaume Cartron et al.
CLINICAL CANCER RESEARCH (2016)
Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion
Adrian Tempescul et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab
Chikako Shimizu et al.
BREAST CANCER (2016)
The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis
Duo Liu et al.
ANNALS OF HEMATOLOGY (2016)
Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia
Birgit Burkhardt et al.
ANNALS OF HEMATOLOGY (2016)
Targeting FcγRs to treat antibody-dependent autoimmunity
Xiaojie Yu et al.
AUTOIMMUNITY REVIEWS (2016)
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
Geoffrey Liu et al.
CLINICAL CANCER RESEARCH (2016)
FCGR3A and FCGR3B copy number variations are risk factors for sarcoidosis
Jianming Wu et al.
HUMAN GENETICS (2016)
Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis
Michel W. P. Tsang-A-Sjoe et al.
RHEUMATOLOGY (2016)
Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
Anna Maria Trotta et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas
Ludovic Gabellier et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
The platelet Fc receptor, FcγRIIa
Jianlin Qiao et al.
IMMUNOLOGICAL REVIEWS (2015)
Fc receptors: genetic variation, function, and disease
Chantal E. Hargreaves et al.
IMMUNOLOGICAL REVIEWS (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Falk Nimmerjahn et al.
TRENDS IN IMMUNOLOGY (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
George K. Philips et al.
INTERNATIONAL IMMUNOLOGY (2015)
Therapeutic uses of anti-interleukin-6 receptor antibody
Sujin Kang et al.
INTERNATIONAL IMMUNOLOGY (2015)
Therapeutic use of anti-CTLA-4 antibodies
Christian U. Blank et al.
INTERNATIONAL IMMUNOLOGY (2015)
Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis
Gabriela Avila-Pedretti et al.
PLOS ONE (2015)
Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity
Andrew T. Vaughan et al.
BLOOD (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Type I and type II Fc receptors regulate innate and adaptive immunity
Andrew Pincetic et al.
NATURE IMMUNOLOGY (2014)
Functional Fcgamma Receptor Polymorphisms Are Associated with Human Allergy
Jianming Wu et al.
PLOS ONE (2014)
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial
Lise Roca et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Hua Fang et al.
CANCER RESEARCH (2013)
FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity
Rintaro Moroi et al.
IMMUNOGENETICS (2013)
The Cytotoxic Effects of Certolizumab Pegol and Golimumab Mediated by Transmembrane Tumor Necrosis Factor α
Naoyasu Ueda et al.
INFLAMMATORY BOWEL DISEASES (2013)
FcγR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response
Robert Makowsky et al.
PHARMACOGENETICS AND GENOMICS (2013)
Allelic-Dependent Expression of an Activating Fc Receptor on B Cells Enhances Humoral Immune Responses
Xinrui Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Herve Ghesquieres et al.
BLOOD (2012)
Phenotypic Variation in IgG Receptors by Nonclassical FCGR2C Alleles
Joris van der Heijden et al.
JOURNAL OF IMMUNOLOGY (2012)
A genome-wide association study identifies three new risk loci for Kawasaki disease
Yoshihiro Onouchi et al.
NATURE GENETICS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis
James M. Kelley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Copy Number Variation of FCGR3B Is Associated with Susceptibility to Idiopathic Pulmonary Fibrosis
Stylianos Bournazos et al.
RESPIRATION (2011)
Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease
Xu-jie Zhou et al.
INTERNATIONAL IMMUNOLOGY (2010)
Fcγ Receptor IIIb (CD16b) Polymorphisms are Associated with Susceptibility to Idiopathic Pulmonary Fibrosis
Stylianos Bournazos et al.
LUNG (2010)
Transmembrane TNF-α: structure, function and interaction with anti-TNF agents
Takahiko Horiuchi et al.
RHEUMATOLOGY (2010)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
T. Meyer et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population
Kouichi Asano et al.
NATURE GENETICS (2009)
Associations Between FCGR3A Polymorphisms and Susceptibility to Rheumatoid Arthritis: A Metaanalysis
Young Ho Lee et al.
JOURNAL OF RHEUMATOLOGY (2008)
FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity
Manuela Fanciulli et al.
NATURE GENETICS (2007)
Strategies in the management of alemtuzumab-related side effects
Anders Osterborg et al.
SEMINARS IN ONCOLOGY (2006)
FcγRIIa-131R allele and FcγRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy
Y Tanaka et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts
RA Floto et al.
NATURE MEDICINE (2005)
Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents
Z Tutuncu et al.
ARTHRITIS AND RHEUMATISM (2005)
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity
H Nückel et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Severity of Guillain-Barre syndrome is associated with Fcγ receptor III polymorphisms
NM van Sorge et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α
H Mitoma et al.
GASTROENTEROLOGY (2005)
Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes
K Kono et al.
CLINICAL CANCER RESEARCH (2004)
FcγRIIIA-158V and rheumatoid arthritis:: a confirmation study
AW Morgan et al.
RHEUMATOLOGY (2003)
Fc gamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura
MD Carcao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus -: Contribution of FCGR2B to genetic susceptibility
C Kyogoku et al.
ARTHRITIS AND RHEUMATISM (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome
WL van der Pol et al.
NEUROLOGY (2000)
Share Paper
